BioSpace News Archive

CANTEL MEDICAL CORP. announced an estimated revenue range for the company’s fiscal fourth quarter, which ended July 31st, 2020.

- Completed commercial-scale drug substance PPQ campaign ahead of schedule, enabling the expected on-time completion of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 - - Expect to submit clinical module of rolling BLA for teplizumab in Q3 2020 - - Extended follow-up results from the pivotal “At-Risk” TN-10 Study presented at ADA demonstrated that teplizumab significantly delays the onset of insulin-dependent T1D by a median of

-- EYSUVIS™ NDA Accepted by FDA; Assigned PDUFA Goal Date of October 30, 2020 -- -- 2Q 2020 INVELTYS ® Revenue of $0.8 Million -- -- Conference Call and Webcast at 8:00 a.m. ET -- WATERTOWN, Mass.--( BUSINESS WIRE )-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the se